• StorEn Technologies Inc. delivers proprietary vanadium flow batteries offering a variety of benefits over existing lithium and lead acid batteries
• The company’s growing intellectual property portfolio currently features four international PCT patents and five trademarks
• The total investment in the company’s technology has exceeded $2 million
• StorEn secured a $500,000 order to provide 30 kWh vanadium flow batteries to a renewable hydrogen plant at Queensland University of Technology in Australia
• The global battery energy storage market is forecast to reach $19.74 billion by 2027, recording a CAGR of 20.4% from 2020 to 2027
• StorEn is led by an executive team with decades of experience in the vanadium flow battery industry, including two previous startups exited to listed buyers
• The company is currently accepting investments through a Reg A+ offering on StartEngine Campaign, where it has raised more than $6.7 million from over 5,000 investors to date

StorEn Technologies delivers proprietary vanadium flow batteries aimed at revolutionizing the world of residential and industrial energy storage. With an expected life of 25 years and more than 15,000 cycles, the company’s batteries satisfy market demand for efficient, durable and cost-effective energy storage, enabling self-consumption of self-produced electricity and the transition toward a carbon-free economy. The company is currently accepting investments through a Reg A+ offering on StartEngine. For more information, view the company’s Offering Circular. To date, StorEn has raised more than $6.7 million from over 5,000 investors on the crowdfunding platform, along with venture capital from the ANYSEED Fund. StorEn’s growing intellectual property portfolio currently features four international PCT patents and five trademarks, securing its innovative IP in all major regions and countries in the world. A Disruptive Approach to Energy Storage StorEn’s patent-pending all-vanadium flow battery technology offers a variety of benefits over existing lithium and lead acid batteries, including:

• Eco-Friendly: StorEn vanadium flow batteries are 100% recyclable, featuring a 100% reusable electrolyte and low GHGs emissions
• Safe: The company’s batteries are both non-flammable and non-explosive
• Cost Effective: StorEn’s cost/kWh is comparable to that of lithium batteries, but its cost/cycle is up to four times lower than lithium batteries, thanks to the exceptional duration of over 25 years or 15,000 cycles
• Efficient: The company’s vanadium flow battery technology offers the highest power density thanks to MULTIGRIDS(TM), +35% in energy storage capacity with the same volume and +5% round-trip efficiency in harsh climate thanks to its proprietary THERMASTABLE(TM) geothermal design. StorEn’s solution is also virtually maintenance-free, leveraging its proprietary RESAFE(TM) and EQUILEVELS(TM) technologies.

StorEn batteries are modular and configurable in either 20kWh or 30kWh versions sharing the same Power Module, ensuring that customers only pay for the energy capacity they really need. The ability to connect additional modules allows for maximum flexibility. Traction in the Market To date, the total investment in the company’s technology has exceeded $2 million, and it is already putting these efforts to work. StorEn secured a $500,000 order in Australia to provide 30 kWh StorEn vanadium flow batteries to a renewable hydrogen plant at Queensland University of Technology (QUT), where researchers will develop safety standards for the future use of vanadium flow batteries. The first battery – the first of its kind in Australia – was installed in Brisbane in November 2020 at the National Battery Testing Centre (NBTC), a flagship project of the Future Battery Industries CRC. Additional units are being manufactured. StorEn has also entered into a supply chain deal with Multicom Resources, an Australian mining company which is the owner of two vanadium mines. Through this agreement, StorEn has secured the exclusive availability of vanadium for up to 20 years with either a price cap or at market price, whichever is lower. Capitalizing on the Australian government’s support to fulfil the country’s energy storage opportunity, Multicom’s subsidiary, Freedom Energy, has agreed to assemble StorEn batteries within Australia and distribute them widely across the wider Asia Pacific region. In addition to an initial pilot plant, Multicom has completed a concept design for a full-scale manufacturing facility for StorEn batteries. Market Opportunity The shift to renewable energy sources is on, with governments around the globe discussing and implementing initiatives to reduce dependence on fossil fuels. McKinsey & Company research suggests that, by 2035, more than 50% of global power generation will come from renewable sources. Spurred on by this transition, demand for reliable energy storage systems is expected to attain exponential growth in the coming years, positively influencing the energy storage industry landscape, according to Grand View Research. Data from Fortune Business Insights projects that the global battery energy storage market will reach $19.74 billion by 2027, recording a CAGR of 20.4% from 2020 to 2027. The research firm suggests that improving access to electricity across the globe will be a prominent trend shaping the growth trajectory of this market, which is particularly noteworthy for StorEn and its TITANstack™ grid-scale energy storage solution. Over a billion people still do not have access to electricity. The electrification of these unserved communities can become a reality with mini grids, using solar plus energy storage. StorEn’s vanadium flow batteries could be a key technology toward providing universal access to affordable, longer lasting and dependable energy. In support this critical mission, StorEn Technologies is a member of the Alliance for Rural Electrification and the Global Off-Grid Lighting Association. Management Team StorEn is led by an executive team with decades of experience in the vanadium flow battery industry. Founder Carlo Brovero has served as the company’s chief executive officer, treasurer and director since its inception in January 2017. From 2013 to 2019, Mr. Brovero served as a consultant for eCaral Ltd., a management consulting firm. From 2013 to 2015, he served as an advisory board member for Proxhima S.r.l., a vanadium flow battery company, which was sold to the Gala Group, a utility listed on the Milan Stock Exchange. From 2010 to 2016, Mr. Brovero served as International Sales and Marketing Director for iVis Technologies, the manufacturer of an excimer laser therapeutic and refractive platform for corneal surgery. He holds an MBA from Aston University in Birmingham, UK. Founder Angelo D’Anzi has served as StorEn’s chief technology officer and director since the company’s inception. He is primarily responsible for the technical development of StorEn’s products. Since May 2018, Mr. D’Anzi has also served as a director of Arco Fuel Cells S.r.l., where he is responsible for the company’s fuel cell technical development activities. Mr. D’Anzi co-founded vanadium flow battery company Proxhima in 2013. In 2000, he founded ROEN-EST, a fuel cell company that was eventually acquired by the Morphic Group, a cleantech holding company listed on the Stockholm Stock Exchange. Mr. D’Anzi holds 14 international patents and received the 2003 Sapio Award in the Energy and Transportation category. He holds an MBA from the LUISS Business School in Rome. Founder Gabriele Colombo has served as secretary of StorEn since its inception. Since 2012, he has also served in various roles ranging from regional manager to CEO with Leonardo Hispania S.A., a subsidiary of the Leonardo Group of Italy, an aerospace, defense and security conglomerate. Mr. Colombo co-founded vanadium flow battery company Proxhima in 2013. He holds an honors degree in computer engineering from the University of Pisa and a master’s degree in business leadership from the University of Genova. For more information, visit the company’s website at www.StorEn.tech. NOTE TO INVESTORS: The latest news and updates relating to StorEn Technologies are available in the company’s newsroom at https://ibn.fm/StorEn

• Bladder cancer is still the sixth most prevalent cancer in the U.S. in 2021
• The total number of new bladder cancer cases is expected to reach 83,730, with deaths totaling 17,200 this year
• Imagin Medical Inc. is hoping to offer a better standard of care for bladder cancer patients with its i/Blue Imaging System(TM) that improves visualization for resection, potentially lowering recurrence rates

According to American Cancer Society statistics, the number of cases of all types of cancer this year will total almost 1.9 million, with 608,570 deaths, or approximately 5,200 new cases and 1,670 deaths per day (https://ibn.fm/eDdCz). Of those numbers, bladder cancer remains the sixth most prevalent form of cancer in the United States, with an estimated 83,730 (4.4% of total) new cases and 17,200 (2.8% of total) estimated deaths in 2021 and a greater than 50% recurrence rate. The five-year relative survival rate (2010-2016) was reported at 77% – meaning that only 77% of diagnosed patients survived five years after diagnosis (https://ibn.fm/Y9NoK).

One company, Imagin Medical (CSE: IME) (OTCQB: IMEXF), is looking to disrupt the industry, changing how cystoscopies for bladder cancer are performed, with the goal of potentially lowering recurrence rates and ultimately helping improve patients’ lives and long-term outlook. The company’s i/Blue Imaging System(TM) is a breakthrough cancer visualization technology currently in the manufacturing stage with Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified contract manufacturer located in Maine. The project is on track for completion in 2022 (https://ibn.fm/q6YMg).

When patients present with symptoms that may be consistent with bladder cancer or other urinary-related conditions, the first step may be to perform a cystoscopy. The first symptom most commonly associated with bladder cancer is hematuria or blood in the urine. When coupled with other symptoms, doctors will perform further evaluations. These additional symptoms may include, but are not limited to:

• A need to urinate that is more frequent than usual
• Pain or burning during urination
• Feeling as if you need to urinate, or an increased urgency to urinate, even without a full bladder
• Having trouble urinating or a weak urine stream
• Needing to urinate many times during the night

For decades, cystoscopies have traditionally used white light illumination for visualization within the bladder. With this white light system, surgeons can visualize the bladder wall and detect and resect any protrusions or correct any inconsistencies, if necessary. However, flat tumors that do not protrude above the wall of the bladder cannot be visualized with white light alone, making it very difficult to perform a complete resection.

The introduction of blue light cystoscopies in 2010 has helped address this issue. Blue light cystoscopies use an FDA-approved contrast agent inserted into the bladder about an hour before the procedure. Once exposed to the blue light, the agent causes the cancerous cells to fluoresce, providing clear images of flat tumors and the margins. Blue light cystoscopy isn’t without its limitations – the current model on the market requires the surgeon or urologist to change views from white to blue light images to operate because the blue light image is not in real time and neither image provides proper orientation of the cancer within the bladder during resection. In addition, the cost of the current method is high and requires the purchase of proprietary, blue filtered cystoscopes that cannot be used for any other purpose.

Imagin Medical’s i/Blue Imaging System has the potential to revolutionize current cystoscopies by showing both white light and blue light images simultaneously side-by-side on the screen in real time, providing clear visualization of the fluoresced flat cancer cells and margins, in context within the bladder. This capability eliminates surgeons’ need to change between images and can potentially lead to lower recurrence rates and help assure a better standard of care and future for bladder cancer patients. In addition, the i/Blue System will come at an overall lower system cost and, because it will adapt to most endoscopes on the market, will allow hospitals and doctor’s offices to make use of scopes they already own, adding to the savings.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• As cultural institutions are closing down because of the pandemic, they are facing an increased security threat, as reduced staffing made them more vulnerable to thieves
• The issue was brought to the forefront after Singer Lauren museum in The Netherlands became the victim of a “smash-and-grab” theft of a priceless piece, The Parsonage Garden at Nuenen in Spring 1884, by Vincent van Gogh
• Knightscope’s technology can successfully increase security in multiple venues, including museums, libraries, galleries, and other cultural institutions
• The company’s autonomous security robot (“ASR”) offering includes K1 (stationary and provides temperature monitoring), K3 (indoor machine), and K5 (outdoor machine), all capable of being implemented into a museum setting

The COVID-19 pandemic is responsible for the temporary closure of approximately 90% of the world’s museums. According to research by UNESCO and the International Council of Museums, this percentage represents approximately 85,000 museums, 13% of which may never reopen. One alarming part of the equation is that due to the closures, the workforces of museums, libraries, galleries, and other cultural institutions that are in charge of these valuable pieces have found themselves at a reduced capacity. These low operational numbers leave such institutions vulnerable from a security standpoint and give thieves the confidence boost they need to make attempts on these valuables (https://ibn.fm/9jzIX). The recent theft of Vincent van Gogh’s The Parsonage Garden at Nuenen in Spring 1884 from Singer Lauren in the Netherlands highlights this issue, raising concern about the threat level to other museums worldwide. The Singer Lauren robbery in March 2020 garnered the attention of museum security staff and directors and resulted in increased monitoring measures and the implementation of 24-hour security operations. Even with the additional measures, however, thieves may still target these institutions, thinking they are in a weakened state because of reduced staffing during the pandemic. Advanced security technology company Knightscope, may be the solution that these institutions are missing to maintain security at all times. Founded in 2013 and based in Mountain View, California, Knightscope is a leader in developing autonomous security capabilities. The company is on target to disrupt the $500 billion security industry through its innovative technology that uniquely combines self-driving technology, robotics, and artificial intelligence (“AI”). Knightscope designs and builds Autonomous Security Robots (“ASRs”) that provide 24/7/365 security to the grounds it patrols, including places where consumers live, work, visit, and study. These ASRs have even assisted in the arrest of suspects involved in crimes that range from armed robbery to hit-and-runs. Implementing one of the Knightscope ASR designs in a museum, library, gallery, or another cultural institution is part of the very foundation of the ASRs’ designs, and could significantly help enhance security on these properties all while maintaining pandemic-imposed staffing restrictions. Knightscope’s current offering consists of K1 (stationary machine), K3 (indoor machine), and K5 (outdoor machine). The company has eight patents alongside a framework of intellectual property. The autonomous ASRs patrol client sites without remote control and provide a visible, force-multiplying, physical security presence. This presence is beneficial in protecting assets (like priceless paintings), monitoring for any physical changes within the patrol area, and the deterrence of crime. The data collected is accessible through the Knightscope Security Operations Center (“KSOC”). This intuitive and browser-based interface allows for security officials to review events monitored by the ASRs. All ASRs and technology associated with the Knightscope name are developed from the ground up and made in the USA. When cultural facilities reopen their doors to the public, implementation of Knightscope’s K1 unit can help with monitoring elevated body temperature (“EBT”), providing private alerts, and mitigating potential exposure. Not only can the assets be kept safe, but so can the patrons inside. Knightscope’s technology is on the forefront of helping America reopen safely for both staff members and the general public. For more information, visit the company’s website at www.Knightscope.com and if you have a need for subscription service you may request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Nextech AR released its Q1 2021 financial and operating results after the markets closed on May 12, in line with an earlier commitment
• The company subsequently hosted a conference call in which the CEO and CFO discussed the results and responded to questions
• A recording of this live presentation will be available on Nextech’s website
• Nextech recently announced a partnership with Concordia University and CUCCIO to host the first-ever virtual Canadian Higher Education Information Technology (“CANHEIT”) conference

In an earlier communication, Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF) had intimated that it would release its audited financial results on or around May 13. In line with this position, the company announced its first quarter 2021 financial results after markets closed on Wednesday, May 12, 2021. Providing the crucial facts and resources needed by analysts and investors, Nextech subsequently hosted a conference call in which CEO Evan Gappelberg and Chief Financial Officer Kashif Malik discussed these financial and operating results, and fielded questions during a scheduled Q&A session. To cater to those who were unable to join the live event, Nextech is making available on its website a recording of this earnings call. As one of the leaders in the rapidly growing augmented reality (“AR”) industry, Nextech is focused on creating an AR ecosystem that can be used in advertising, video conferencing, e-commerce, education, and training. Basing its operations on this focus, NTAR has offered its services to multiple companies and organizations such as TEDx, Vulcan Inc., Arch Insurance, UNESCO, Amazon (NASDAQ: AMZN), Bell Canada (NYSE: BCE), Dell Technologies (NYSE: DELL), Viacom (NASDAQ: VIAC), Johnson and Johnson (NYSE: JNJ) and more. The company recently added a new entry to this list of clients when it announced its Virtual Experience Platform (“VXP”) has been selected to host this year’s virtual Canadian Higher Education Information and Technology Conference (“CANHEIT”) to be held May 31-June 4 (https://ibn.fm/91XE6). CANHEIT is a national conference for IT professionals in higher education, including staff, managers and senior administrators, mandated with the management and advancement of their institutions’ digital infrastructure, as well as information and learning systems. During the conference, to be hosted in partnership with Concordia University and CUCCIO, these professionals will showcase best practices and collaborate. This year’s CANHEIT will be one of a kind because, in addition to being the first-ever virtual event in the conference’s history – a departure from the traditional in-person event practice – Nextech is committed to making it memorable and immersive through its VXP platform. This platform will enable attendees to access interactive virtual networking spaces, a virtual exhibitor hall with 30-40 chat-enabled exhibitor booths and breakout rooms. Additionally, being an AR technology provider, Nextech will offer attendees an AR experience through AR portals available on the VXP platform, which will enable them to enter a virtual world and subsequently experience Concordia University as if they were there in person. “It’s been a fantastic experience organizing the first-ever virtual CANHEIT conference with a company like Nextech,” commented Associate Vice President and CIO of Concordia University France Bigras. “As we continue to adapt to an ever-changing world of virtual learning and interactivity, it was important for us to select a robust all-in-one solution to host our premier event and provide attendees and sponsors alike with a truly unique experience.” Nextech takes pride in the fact that its VXP platform has exceptional AR/VR capabilities that, when combined with its comprehensive objective of creating novel and exciting ways of bringing global communities together, have enabled it to support numerous virtual and hybrid conferences and events. The company is committed to offering an immersive experience for event attendees, thereby bridging the gap between the physical and digital world. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• Company announces renegotiation of $4.2 million of convertible notes
• Report shows net revenues of $3,672,353 for the year ended Dec. 31, 2020, an increase of $3,221,157 over 2010 revenues
• GPFT looks forward to growing distribution business, ushering in the age of Hourglass

After spending the last six weeks renegotiating key terms of an estimated $4.2 million of convertible notes, Grapefruit USA (OTCQB: GPFT) announced its financial results for fiscal year 2020, the period ended Dec. 31, 2020 (https://ibn.fm/ZxUxa). In addition to the restructure of the convertible debt, a highlight of the report in was the company’s 714% year-over-year revenue growth. “We are pleased to report net revenues of $3,672,353 for the year ended Dec. 31, 2020, an increase of $3,221,157 or 714% over revenues of $451,196 for the year ended Dec. 31, 2019, despite operating during a global pandemic,” said Grapefruit CEO Brad Yourist. “We are also heartened to report that over the last several weeks we have been engaged in an exercise in holding the line for our company and its loyal shareholder base with respect to renegotiating the notes with our institutional investor. We think we have achieved a very positive result and look forward to continuing to grow our distribution business and to fully usher in the age of Hourglass, our remarkable cannabinoid hemp-based CBD and THC topical time release delivery system.” According to the announcement, Grapefruit began renegotiating the terms of the notes after an audit showed that the notes contained a variable conversion price feature that would force in the company to recognize a noncash loss in excess of $40 million for FY2020. Discussions between company management and the company investor resulted in an agreement to modify the notes, thus eliminating the variable conversion price feature. As a result of the modifications, an estimated $40 million noncash loss for the year 2020 was eliminated; complete details of the agreement are available in Grapefruit’s annual report (https://ibn.fm/1iVes). “We look forward to more success in 2021, which is already off to a superb start and will shift into high gear in the next few days with Grapefruit’s live launch of its retail hemp-derived CBD products website featuring our disruptive hemp CBD based Hourglass products,” said Yourist. “In addition, we have been informed by our Canadian joint venture/potential acquisition group that their shareholder’s meeting will be held this week as previously reported and at the conclusion of which our discussions will restart immediately. Further updates with respect to the new Grapefruit hemp-based CBD Hourglass retail website live launch and Canadian JV/acquisition progress will be provided in real time.” Hourglass is a patented, disruptive gamechanger in the recreational and medicinal cannabis and CBD market. Grapefruit is devoted to selling only high-quality, laboratory tested, and reliable products. All of Grapefruit’s hemp CBD-based products to be marketed and sold on the new e-commerce website will be tested and come with a QR coded Certificate of Analysis, which provides consumers with certified precise and accurate labeling of the product’s cannabinoid content, purity, and safety. To find out more about the company and its game-changing Hourglass time-release cannabinoid delivery cream, please visit  www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

• Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needs
• Tryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagia
• The company is also developing a clinical trial to address the needs of fibromyalgia patients who often rely on opioids to relieve their symptoms
• Tryp has announced two new collaborations for oversight of the drug trials this month; consultants with Fluence and Clinlogix will help to ensure the quality of the tests

Bioscience pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), pursuing its goal of developing psychedelic drug treatments for diseases that otherwise have unmet medical needs, is continuing to prepare for an upcoming Phase 2a clinical trial for treating eating disorders by forging partnerships with professionals experienced in conducting such trials.

The company’s recent announcement that it will collaborate with psychedelic therapy educational platform Fluence in a master service agreement to provide design and training for the psychotherapeutic portion of the upcoming trials follows on the heels of Tryp’s agreement with the University of Florida to conduct the clinical trial.

Pediatric medical researcher Jennifer Miller, M.D., of the University of Florida is leading the investigation into the potential of Tryp’s TRP-8802 psilocybin product for safety, pharmacokinetics and efficacy. Miller is an expert in certain eating disorders including binge eating and hyperphagia.

“There are currently no approved drugs and only limited options to treat patients with rare over-eating disorders,” Miller stated in a news release announcing the collaboration (https://ibn.fm/rSnYK).

The company’s upcoming Phase 2a trial for fibromyalgia patients is designed to provide an alternative treatment option for the large number of patients currently relying on opioids to relieve their symptoms.

Fluence is led by researchers and psychotherapists with direct experience in conducting psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic compounds to patients, according to another news release issued May 3 (https://ibn.fm/SO55k).

“In the fast-moving arena of psychedelic therapies, Fluence has established themselves as the leader in psychotherapy design and training,” Tryp President and Chief Science Officer Jim Gilligan stated in the news release. “Psychotherapy is an essential component of the effective administration of our innovative psilocybin formulations for the chronic pain and eating disorder indications that we are pursuing. Fluence’s experience with training hundreds of clinicians combined with the training protocol they are creating with Tryp will help create a safer and more effective treatment protocol for our clinical trials and ultimately for patients suffering from these conditions.”

Additionally, Tryp announced May 10 that Contract Research Organization (“CRO”) Clinlogix will provide support services for the upcoming Phase 2a trials (https://ibn.fm/V0Zr7). Clinlogix has developed experience in providing CRO services for the development of novel pharmaceutical products on a global basis, and the master service agreement between Tryp and Clinlogix will support the development of Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFNTM”) program, according to the announcement.

“The proper execution of a clinical study is of paramount importance in order to achieve clinical success; working with the team from Clinlogix provides Tryp with key elements needed for the conduct of a successful clinical study,” Gilligan added.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

 

• SRAX Inc. will host conference call to announce Q1 2021 results on May 17, 2021
• Call will be hosted via live video call, will also feature question & answer session
• SRAX released Q4 2020 results earlier this year, revealing 316% YoY increase in revenues, upping its 2021 sales guidance to $23-25 million

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, is scheduled to host a conference call to discuss its Q1 2021 results on May 17th, 2021. The call will feature SRAX Founder and CEO Christopher Miglino as well as SRAX CFO Michael Malone, who will provide investors with an operational and financial summary of their quarterly earnings on a live video call, along with hosting a question-and-answer session, on May 17, 2021 at 1:30 pm PT/4:30 pm ET (https://ibn.fm/wHuuS).

SRAX has seen its financial returns go from strength to strength over the past year. Earlier this year the Company released its Q4 2020 results (https://ibn.fm/rP4Mm). At the time the Company reported Q4 revenues of $4.5 million, up 316% year-over-year whilst simultaneously reporting Q4 net income of $200,000, a significant increase relative to the net loss of -$4.4 million witnessed in Q4 of 2019.

SRAX also seized upon the opportunity to raise its FY2021 revenue guidance to $23-25 million, a substantial increase from its previous guidance of $17-18 million, implying a growth rate of between 164-187% year-over-year for FY2021.

SRAX also provided an update on Sequire at the time, revealing that the investor intelligence platform had secured bookings of $4.8 million and $10 million for the fourth quarter of 2020 and first quarter of 2021, respectively, whilst also seeing its corporate subscriber base swell to 183 publicly listed companies (versus 92 companies as of their Q3 2020 update). SRAX also announced that Sequire would recognize $16.5 million in revenues based on its existing contracts over the course of the 2021 fiscal year.

“We are making great progress with our platform and we are seeing continued adoption of the products that we are building for issuers,” stated SRAX CEO Christopher Miglino following the Company’s Q4 2020 results. “We had another record quarter of bookings for Sequire. In the first quarter of 2021 we have closed over $10 million in contracts.”

SRAX has taken several steps to augment and streamline its operations over the past few months, including naming entrepreneur and 2020 presidential candidate Brock Pierce to the Company’s board of directors, divesting an equity stake in TI Health (formerly known as SRAXmd), and announcing a substantial line-up of investor conferences to be held via the Sequire platform over the coming year.

With Sequire’s popularity rising to new heights among both corporate issuers and investors alike, SRAX stands well poised to benefit from its success.

To register for the live webcast and view the presentation, please sign up at the following link: https://Q12021earningscall.mysequire.com.

Investors who would like to access the earnings call by phone can use the following details:

Phone Number: +1 669-900-6833 | Webinar ID: 959-8207-6042 | Passcode: 288501

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Clean Power Capital Corp.’s investee company PowerTap Hydrogen Fueling to employ its patented hydrogen production technology in several commercial markets
• PowerTap utilizes data analytics to control PowerTap’s system performance
• PowerTap aims at installing 500 hydrogen filling stations in the USA alone within the next 3-5 years

Clean Power Capital (NEO: MOVE) (FWB: 2K6A) (OTC: MOTNF) is an investment holding company that focuses on investor and finance opportunities across renewable energy, bio-medical, pharmaceutical, and naturopathic sectors. The company’s investments are geared towards short-term gains, income generation, or long-term capital appreciation, with the main objective to generate maximum returns from its investments.

PowerTap Hydrogen Fueling Corp., an Investee Company Of Clean Power Capital, holds a unique and patented hydrogen production technology (PowerTap). PowerTap is focused on building affordable hydrogen fueling infrastructure through its eco-sustainable and expandable product design for the modularized and onsite hydrogen production facility and launch plan.

A previous generation of PowerTap technology is already operational (not owned by PowerTap Hydrogen Fueling Corp.) across several hydrogen fueling stations in the public and private enterprises of California, Massachusetts, Maryland, and Texas. With this business model, Powertap Hydrogen Fueling aims to operate up to 500 hydrogen filling stations in the USA alone within the next 3-5 years. As per the company’s latest announcement, the PowerTap’s 3rd generation units will be utilized towards several commercial markets.

As a part of its progressive expansion plans, PowerTap has started initial discussions with various cities, states/provinces about partnerships with new verticals such as commercial buses and trains. The company’s 3rd generation onsite hydrogen production module will be made available to hydrogen fuel cell cars and trucks and provide blue hydrogen for trains and buses.

The expanding hydrogen public bus fleet is another vertical that could leverage PowerTap’s blue hydrogen production and dispensing technology. Pioneers in operating a hydrogen fuel-cell electric bus2, the Orange County, California Transit Authority (“OCTA”) is a public transportation agency in Southern California.  During the model program, OCTA operated the first hydrogen bus in a similar way to the other OCTA buses in the fleet.  According to the California Fuel Cell Partnership, fuel cell buses are environmentally-sustainable with lesser noise, no local emissions, and a substantial reduction in greenhouse gas emissions (https://ibn.fm/T7KIE).

As a further step-up to the potential of PowerTap’s 3rd generation units, these modules will use advanced operating software with data analytics to control every aspect of PowerTap’s system performance. Kelley Owen, PowerTap’s Chief Operating Officer stated that the advancements of the PowerTap 3rd generation hydrogen production fueling stations will maximize the company’s first-mover advantage.

PowerTap employs advanced operating software to collect and feed data to the cloud where a data analytics application will deploy advanced algorithms to monitor performance characteristics.  This will result in the substantial reduction of extending the longevity of the 3rd generation units while reducing the overall cost of onsite hydrogen production (https://ibn.fm/TFlTU).

For more information, visit the company’s website at www.CleanPower.Capital.

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• World Nuclear Association notes that new nuclear builds offer advantages that extend beyond simply being clean, reliable source of energy
• With growing demand for carbon-free energy production, growing reliance on nuclear seems certain
• Uranium, the fuel most widely used to power nuclear plants, will become an increasingly vital mineral

While COVID-19 still looms as a potential threat in parts of the world, some positive signs indicate that the worst might be over. In its “World Nuclear Performance Report 2020,” the World Nuclear Association noted that, in a post-pandemic world, new nuclear builds offer advantages that extend beyond simply being a clean, reliable source of energy. Uranium Energy (NYSE American: UEC) stands ready to support and contribute to growth in the nuclear energy space.

“In 2020 the nuclear industry has been an essential part of the response to the coronavirus pandemic,” writes World Nuclear Association director general Agneta Rising in the preface to the report. “Despite the challenges of working in COVID-safe conditions, nuclear operators have ensured reactors have been available to provide electricity and grid stability. Reactor operators have also had to respond to the marked reductions in demand that have been observed during the pandemic and have had to operate with more flexibility. . . .

“Looking forward, governments are considering at how to restart their economies and generate jobs, as well as how to meet their energy and environmental goals,” Rising continues. “Each new nuclear build project generates thousands of jobs and boosts the local economy, as well as contributes to our harmony goal of a clean and reliable electricity mix.”

The performance report (https://ibn.fm/NVpMo) noted that electricity generated from the world’s nuclear reactors increased for the seventh consecutive year in 2019, reaching the second highest output ever. With a growing demand for carbon-free energy production and the safe, clean and highly reliable energy that nuclear power provides (https://ibn.fm/1j1ik), new nuclear builds seem certain.

With those new builds will come a greater need for uranium, the fuel used to power nuclear plants. Uranium Energy Corp, a U.S.-based uranium mining and exploration company, is poised to benefit from the increased demand projected for uranium. The company has fully licensed projects in Texas and Wyoming with a production profile of 4 million pounds per year, enough to power about eight of America’s 93 commercial reactors. UEC has a solid balance sheet with over $110 million in cash, equity and inventory holdings. They control one of the largest databases of historic uranium exploration and development in the United States, an invaluable resource as the company has been able to identify potential acquisition properties that have already been the subject of significant exploration and development in the past.

UEC is positioned as the leader in U.S. low-cost, environmentally friendly and fully permitted In-Situ Recovery (“ISR”) projects (https://ibn.fm/erkyy). Their Burke Hollow project’s initial production area is amongst the largest uranium ISR wellfields ever developed in the 45-year history of uranium mining in South Texas. The low-impact ISR method of uranium recovery being developed at Burke Hollow is the most environmentally friendly way to mine uranium which is now responsible for approximately 50% of global production (https://ibn.fm/6FkaI).

Founded in 2003, UEC is headquartered in Corpus Christi, Texas. Properties acquired by the company are primarily located within the United States, including Texas, New Mexico, Colorado, Arizona and Wyoming. In addition, the company is aggressively pursuing other key developmental targets. UEC is investing to be a next-generation uranium producer, and is committed to providing low-cost, low-capital fuel for the country’s large electricity-generating nuclear fleet.

For more information, visit the company’s website at www.UraniumEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC

• Imagin Medical’s contract manufacturer, Lighthouse Imaging, has developed a program focused on refining the i/Blue System’s design for manufacturing
• Lighthouse’s manufacturing process will ensure that regulatory standards are followed while maintaining optimal performance and staying within targeted costs
• Imagin is currently focusing on using the i/Blue system for bladder cancer visualization with plans to extend the use of the technology to other procedures in the future

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is on track to complete its patented i/Blue Imaging System(TM) in 2022. The innovative technology leverages proprietary light sensors and optics to improve the accuracy and efficiency of bladder cancer visualization and removal, potentially reducing recurrence rates.

The manufacturing progress reported to-date can be largely attributed to the company selecting Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified manufacturer, as its contract manufacturer. According to a press release, Lighthouse’s development program is focused on refining the i/Blue system’s design to ensure that the final device complies with all regulatory standards while maintaining optimal performance and remaining within a target cost and anticipated demand (https://ibn.fm/B6kXW).

Imagin Medical Director of Engineering and Quality Mike Vergano explained that the company chose Lighthouse to help move the i/Blue System into commercial manufacturing because of its cross-functional expertise in electronics, optics, software and mechanical design. He added that Imagin was very satisfied with Lighthouse’s manufacturing progress: “We have not been disappointed. The Lighthouse team’s work to-date has been exceptional, and we look forward to that continuing.”

Imagin President and CEO Jim Hutchens also said his company expected Lighthouse to remain on schedule and meet all manufacturing targets. This year’s primary goal is the completion of the final pre-production i/Blue Imaging System unit, as outlined by Hutchens in a press release earlier this year. The company’s secondary goals include establishing final test parameters for the technology with the FDA, continuing to develop relationships with opinion leaders in the field and expanding its intellectual property platform (https://ibn.fm/ZwUKV).

While the company has plans to expand its technology to other minimally invasive procedures, the primary focus for now is on bladder cancer, one of the most expensive forms of cancers to treat. Bladder cancer is the sixth most prevalent cancer in the U.S., with one of the highest recurrence rates, greater than 50%. In 2020, there were 81,400 new cases reported and approximately 17,980 deaths (https://ibn.fm/lwm6S).

The current standard of treatment for bladder cancer is the cystoscopy, a procedure that allows doctors to examine the lining of the bladder by inserting a hollow tube (cystoscope) equipped with a lens into the bladder. Approximately 90% of all cystoscopies use white light which, however, cannot detect all of the cancerous growths if they run flush along the bladder’s lining. Introduced a decade ago, the use of an FDA-approved contrast agent with a blue light filter allows surgeons to better visualize flat surface cancerous growths, enabling a cleaner resection, but has the downside of not showing images in real time, requiring surgeons to switch back between white and blue light images to orient themselves within the bladder.

Imagin Medical’s innovative i/Blue Imaging System, based on advanced optics and light sensors that employ patented ultrasensitive imaging technology, aims to address these limitations by simultaneously displaying white light and blue light images in real time, side-by-side on the screen, providing better visualization for the surgeon and potentially lowering recurrence rates. Additionally, the i/Blue Imaging System adapts to most endoscopes already on the market, thus providing a more cost-effective solution for hospitals.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF